TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00904891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group
Description: Six sessions of cognitive-behavioral depression prevention group intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral bibliotherapy
Description: Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good
Study: NCT01364597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Description: The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
Study: NCT04266639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning
Description: RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: Sham Comparator (Sham-RIC)
Study: NCT04458623

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Air Test
Description: .The Air-Test may represent an accurate, simple, inexpensive and non-invasive method for diagnosing postoperative atelectasis.
Study: NCT02877810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedicine is a live, interactive, audiovisual teleconferencing system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone
Description: Consultations will be given over telephone.
Study: NCT03843749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib in Combination With Trastuzumab
Study: NCT01598090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a
Description: Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a
Description: Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
Study: NCT04078360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention
Description: The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~1. Self awareness messages~2. Self reflection messages~3. Motivational messages~4. Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~5. Health education messages~6. Personalized feedback and information~7. Help-seeking resources~8. Goal setting messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face Brief Intervention
Description: The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI leaflet intervention
Description: The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
Study: NCT01598090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
Study: NCT04601441

Intervention type: DRUG
Group type: OTHER
Intervention: Apalutamide
Description: Apalutamide 240 mg administered orally once a day as four 60 mg tablets
Study: NCT01949103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607
Study: NCT01598090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablets, Oral, 750 mg, three times a day, 12 weeks only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablets, Oral, 750 mg, three times a day, 12 weeks only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablets, Oral, 750 mg, three times a day, 12 weeks only
Study: NCT01949103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03379753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music and positive images
Description: The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
Study: NCT01949103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04173767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula ventilation
Description: High-flow nasal cannula (HFNC) ventilation therapy: supply heated \& humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
Study: NCT01423786

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Early Oral Nutrition
Description: Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
Study: NCT00113360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Starting dose of 5 or 10 mg by mouth daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Depot
Description: 30 mg injection into the muscle of either buttock once every 28 (±7) days.
Study: NCT02481375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Description: 12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple micronutrients
Description: 12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
Study: NCT01024868

Intervention type: DRUG
Intervention: Ropivacaine 0,5%
Description: Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
Study: NCT02481375

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: 12-wk supplementation of iron

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: 12-wk supplementation of iron

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12-wk supplementation of placebo
Study: NCT05134350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: LOXO-305 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: LOXO-305 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Orally.
Study: NCT03573310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64619178
Description: JNJ-64619178 capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64619178
Description: JNJ-64619178 capsules to be administered orally.
Study: NCT00910208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Description: Intravenous morphine delivered via Curlin painsmart PCA device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Description: Intravenous morphine delivered via Curlin painsmart PCA device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Intravenous morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: Intravenous morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: Intravenous morphine
Study: NCT02568020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: keto-amino acids
Description: Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
Study: NCT04133636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-68284528
Description: Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.
Study: NCT02244463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Study: NCT04133636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants in Cohorts E and H will also receive bortezomib subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.
Study: NCT03690830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: metabolomics analysis
Description: collect blood samples and endometrial cells
Study: NCT03690830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: metabolomics analysis
Description: collect blood samples and endometrial cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metabolomics analysis
Description: collect blood samples and endometrial cells
Study: NCT01356316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S Vaccine 2010-2011
Description: Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
Study: NCT00353613

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Package of targeted interventions to reduce error
Description: Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Package of targeted interventions to reduce error
Description: Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
Study: NCT01605760

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: immunotherapy Staloral
Description: Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: immunotherapy Staloral
Description: Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
Study: NCT03351738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5884
Description: Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5884
Description: Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5884
Description: Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5884
Description: Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
Study: NCT03268382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion
Study: NCT03821714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid combination therapy
Description: Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: The glucocorticoid group was defined as the use of hydrocortisone alone.
Study: NCT02782065

Intervention type: OTHER
Intervention: Not an interventional study
Study: NCT00489086

Intervention type: DRUG
Group type: OTHER
Intervention: tazarotene
Description: Tazarotene is a member of the acetylenic class of retinoids.
Study: NCT02291601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: comparison with other CHG products

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Excipients of CHG product only.
Study: NCT03351738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5884
Description: Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
Study: NCT03213990

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous infusion
Description: Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU

Intervention type: OTHER
Group type: OTHER
Intervention: Intermittent infusion
Description: Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
Study: NCT02322541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garlic Intervention
Description: Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
Study: NCT03399799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Participants will receive IV infusion or SC injection of Talquetamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Participants will receive IV infusion or SC injection of Talquetamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Participants will receive IV infusion or SC injection of Talquetamab.
Study: NCT02291601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DynaHex-2
Description: 2% CHG solution
Study: NCT02260128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: The intervention group will receive chewing gum four times daily following surgery.
Study: NCT03149133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy hypertrophy training
Description: Training with 75-80 % of 1-RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light hypertrophy training
Description: Training with 35-50 % of 1-RM
Study: NCT03116555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was used as second line treatment with AGC
Study: NCT04123535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Description: The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
Study: NCT02141412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 0.25 µg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 0.5 µg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 1 µg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
Study: NCT03998683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: Guselkumab 100 mg will be administered as SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab 100 mg
Description: Guselkumab 100 mg will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as SC injection.
Study: NCT03266822

Intervention type: OTHER
Intervention: No intervention
Description: Observational study
Study: NCT00767728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulated mesalamine
Description: 0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
Study: NCT00435487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin ( Fragmin)
Description: Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg \[units per kilogram\] and initial infusion of 12 U/kg/h \[units per kilogram per hour\]).
Study: NCT03483961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/unadjuvanted
Description: Vaccine consists of virus-like particles of chikungunya virus antigens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel
Study: NCT03355430

Intervention type: PROCEDURE
Intervention: combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)
Description: After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).

Intervention type: PROCEDURE
Intervention: accelerated corneal collagen cross-linking (CXL)
Description: After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).